Current Nivolumab News and Events

Current Nivolumab News and Events, Nivolumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 5 | 178 Results
Therapeutic PD-1 cancer vaccine shown to be safe and effective in animal study
A study led by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor. (2020-11-23)

Rare angiosarcoma tumors respond well to immunotherapy combination
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute's (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination. (2020-11-13)

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) . (2020-11-11)

Immunotherapy combo halts rare, stage 4 sarcoma in teen
The patient, whose tumor responded within two weeks after receiving the combination, resumed normal activity and was in a complete remission at the time of the report. (2020-10-16)

Virus-mimicking drug helps immune system target cunning cancer cells
UCLA researchers found that a drug that activates the body's natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy. (2020-10-14)

New first-line treatment option for metastatic kidney cancer
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020. (2020-09-19)

Immunotherapy combination improves outcomes in advanced kidney cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer. (2020-09-19)

UCLA study shows how interferon-gamma guides response to cancer immunotherapy
UCLA researchers shed light on how interferon-gamma (IFN-y) guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -- immune checkpoint blockade. (2020-09-10)

Combination immunotherapy benefits subset of patients with advanced prostate cancer
esults from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer. (2020-09-10)

checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium. (2020-08-08)

City of Hope, TGen looking to create personalized roadmaps for treatment of kidney cancer
Experts at City of Hope and the Translational Genomics Research Institute (TGen) are using one of the world's most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients. ''The hope is to one day identify patients who will benefit from immunotherapy and those who will not. Eventually we may be able to distinguish which patient is better suited for other treatments, like targeted therapy,'' said Sumanta Pal, M.D. (2020-07-22)

Oncotarget: Adoptive cell therapy in combination with checkpoint inhibitors
Volume 11, Issue 22 of @Oncotarget reported that there are rationale and evidence supporting immune therapy in Ovarian Cancers. The authors investigated the potential for adoptive cell therapy from in vitro expanded tumor-infiltrating lymphocytes in combination with checkpoint inhibitors and conducted immunological testing of ex vivo expanded TILs. (2020-06-10)

Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs. (2020-05-29)

SWOG researchers go digital at ASCO20 Virtual Scientific Program
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31. (2020-05-18)

ECOG-ACRIN research at ASCO 2020
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the annual meeting of the American Society of Clinical Oncology (ASCO), occurring virtually May 29-31. The presentations include late-breaking data in two plenary sessions and several oral abstract presentations. National Cancer Institute, part of the National Institutes of Health, funded these studies. (2020-05-13)

Immunotherapy before surgery could advance care of an aggressive form of skin cancer
In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery. In patients whose tumors respond, this treatment approach offers the potential to reduce the extent of surgery and may also slow or eliminate tumor relapses that often occur after surgery. (2020-04-27)

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society. (2020-03-31)

AI may help predict responses to non-small cell lung cancer systemic therapies
Using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC), researchers utilized artificial intelligence (AI) to train algorithms to predict tumor sensitivity to three systemic cancer therapies. (2020-03-20)

A novel cause of fatty liver in lean people
Nonalcoholic fatty liver disease (NAFLD) is mostly diagnosed in overweight and obese people. However, severe forms of NAFLD can also be detected in rare genetic diseases such as lipodystrophy or in patients with HIV, putting them at a high risk for developing liver failure, diabetes and cardiovascular diseases. Norbert Stefan and colleagues have now detected a yet unknown cause of NAFLD in lean people. (2020-03-03)

Pre-operative immunotherapy triggers encouraging response in oral cancers
A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (2020-02-27)

Immunotherapy combo effective for patients with high-grade neuroendocrine cancer
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial. (2020-02-24)

Math models add up to improved cancer immunotherapy
A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous tumors. (2020-02-03)

NCI-MATCH: Promising signal for nivolumab beyond colorectal cancer
The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH, investigating the activity of nivolumab in tumors with DNA mismatch repair deficiencies. Eighteen different cancer types were studied, mostly rare and none colorectal, with DNA repair defects. The results showed a promising signal for nivolumab beyond colorectal cancer. The 36% response rate across a range of cancers compares well with a previous 31% response in colon cancer. (2019-12-19)

Experimental leukemia combination proves toxic for older, frail patients
About 32% of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the US Food and Drug Administration to eventually pull the combination from the current study. (2019-12-09)

Transition to exhaustion: clues for cancer immunotherapy
Emory research on immune cells 'exhausted' by chronic viral infection provides clues on how to refine cancer immunotherapy. The Immunity paper defines a transitional stage in between stem-like and truly exhausted cells. (2019-12-03)

Prostate cancer bone metastases thwart immunotherapy by producing TGF-β
Prostate cancer that spreads to the bone triggers the destruction of bone tissue that thwarts the effectiveness of immune checkpoint inhibitors. Research points to anti-CTLA-4 and anti-TGF-B combination to protect T cells. (2019-11-14)

Some people with RA treated with immune checkpoint inhibitors for cancer have flare, most able to continue treatment
A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare. However, their rate of experiencing an immune related adverse event is at a rate similar to patients without an autoimmune disease. The study sought to determine the safety and efficacy of immune checkpoint inhibitors in patients with rheumatoid arthritis (RA). (2019-11-09)

Immunotherapy in combination points to paradigm shift in the treatment of cervical cancer
Effective combination of nivolumab with ipilimumab for the treatment of patients with recurrent or metastatic cervical cancer, with or without prior systematic therapies, and irrespective of PD-L1 expression. (2019-09-29)

One in two pts with metastatic melanoma alive after 5 years with combination immunotherapy
One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain. (2019-09-28)

Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates
A combination of 2 immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust. (2019-09-28)

Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC
New data have shown that first-line treatment with a combination of two immunotherapy drugs improves overall survival in a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy. (2019-09-28)

Resistance to immune checkpoint blocker drug linked to metabolic imbalance
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute. (2019-09-25)

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study (2019-09-25)

Electronic nose can sniff out which lung cancer patients will respond to immunotherapy
An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology. (2019-09-17)

Patients taking nivolumab experience five-fold increase in overall survival compared to chemotherapy
Pooled data on two clinical trials demonstrate patients taking nivolumab realized a greater than five-fold increase in five-year overall survival rate compared with the chemotherapy docetaxel. The presentation was made today by Dr. Scott Gettinger of Yale Comprehensive Cancer Center, New Haven, Conn., at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer. (2019-09-10)

Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special populations with advanced non-small cell lung cancer (NSCLC), according to research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. (2019-09-08)

MSI detection via liquid biopsy shows high concordance with results from tissue samples
Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly 1,000 patients. (2019-08-05)

Favorable five-year survival reported for patients with advanced cancer treated with the immunotherapy
A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC). (2019-07-25)

Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center. (2019-06-03)

Stand up to cancer-funded research to be presented at ASCO May 31-June 4 in Chicago
SU2C supported researchers will present work on pediatric brain tumors, cfDNA for early cancer detection, dual blockade of CTLA-4 and PD-1 in mCRC, cancer interception of pancreatic and lung cancers, machine learning RECIST in RWE study of lung cancer, and molecular markers of response to neoadjuvant nivolumab in resectable NSCLC. (2019-05-30)

Page 1 of 5 | 178 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.